Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure

Infect Dis Clin North Am. 2018 Jun;32(2):407-423. doi: 10.1016/j.idc.2018.02.005.

Abstract

The objective of this review is to consider how existing human immunodeficiency virus (HIV) infrastructure may be leveraged to inform and improve hepatitis C virus (HCV) treatment efforts in the HIV-HCV coinfected population. Current gaps in HCV care relevant to the care continuum are reviewed. Successes in HIV treatment are then applied to the HCV treatment model for coinfected patients. Finally, the authors give examples of HCV treatment strategies for coinfected patients in both domestic and international settings.

Keywords: Care cascade; Care continuum; Coinfection; Elimination; Hepatitis C infection; Human immunodeficiency virus.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Coinfection / drug therapy*
  • Coinfection / epidemiology
  • Coinfection / prevention & control
  • Coinfection / virology*
  • Continuity of Patient Care
  • Disease Eradication*
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HIV Infections / prevention & control
  • HIV-1 / drug effects
  • Hepacivirus / drug effects
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology
  • Hepatitis C / prevention & control
  • Hepatitis C / virology*
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / prevention & control
  • Hepatitis C, Chronic / virology
  • Humans
  • Risk Factors
  • United States / epidemiology

Substances

  • Antiviral Agents